Over the past few decades, a rapid and stable increase in cardiovascular implantable electronic devices (CIEDs) rates has been observed. Continuous aging of the population and a wider spectrum of indications with an improved device manufacturing are probably the main factors of the expanding use of CIEDs [1]. However, the higher complexity of the implanted devices and the increasing prevalence of “high-risk” patients with frequent comorbidities have led to an increase in CIED-related infections [2,3].
